{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:55:49Z","timestamp":1788155749852,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.esmoop.2025.106031","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:55:24Z","timestamp":1767617724000},"page":"106031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0412-7143","authenticated-orcid":false,"given":"S.","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.J.-B.","family":"Salomonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Diaz Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Shcherbakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5532-4231","authenticated-orcid":false,"given":"A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sadow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.V.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.esmoop.2025.106031_bib1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.esmoop.2025.106031_bib2","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2025.106031_bib3","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.esmoop.2025.106031_bib4","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.esmoop.2025.106031_bib5","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106031_bib6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.esmoop.2025.106031_bib7","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.2017.73.4186","article-title":"Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015","volume":"35","author":"Jin","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2025.106031_bib8","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1200\/JCO.2012.41.6727","article-title":"Under-representation of older adults in cancer registration trials: known problem, little progress","volume":"30","author":"Scher","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.106031_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.esmoop.2025.106031_bib10","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.3747\/co.25.3978","article-title":"Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?","volume":"25","author":"Al-Baimani","year":"2018","journal-title":"Curr Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106031_bib11","doi-asserted-by":"crossref","first-page":"e721","DOI":"10.1016\/j.cllc.2018.05.014","article-title":"Clinical characteristics and prognosis of patients with advanced non-small-cell lung cancer who are ineligible for clinical trials","volume":"19","author":"Kawachi","year":"2018","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106031_bib12","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/1759-7714.12641","article-title":"Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer","volume":"9","author":"Yoo","year":"2018","journal-title":"Thorac Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106031_bib13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","article-title":"Association of patient comorbid conditions with cancer clinical trial participation","volume":"5","author":"Unger","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2025.106031_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2021.04.004","article-title":"Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials","volume":"151","author":"Gan","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106031_bib15","doi-asserted-by":"crossref","first-page":"9222","DOI":"10.1038\/s41598-021-88453-8","article-title":"Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices","volume":"11","author":"Velcheti","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106031_bib16","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.1038\/s41598-021-85696-3","article-title":"Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands","volume":"11","author":"Cramer-van der Welle","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106031_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.11113","article-title":"Association between first-line immune checkpoint inhibition and survival for Medicare-insured patients with advanced non-small cell lung cancer","volume":"4","author":"Kehl","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106031_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12885-021-08096-w","article-title":"Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom","volume":"21","author":"Lester","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2025.106031_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2021.04.007","article-title":"Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer","volume":"156","author":"Waterhouse","year":"2021","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2025.106031_bib20","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/cancers14030614","article-title":"Real world outcomes versus clinical trial results of durvalumab maintenance in veterans with stage III non-small cell lung cancer","volume":"14","author":"Sankar","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106031_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01100-2018","article-title":"Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer","volume":"52","author":"Cramer-van der Welle","year":"2018","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.esmoop.2025.106031_bib22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.esmoop.2025.106031_bib23","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2025.106031_bib24","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.106031_bib25","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.106031_bib26","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.106031_bib27","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.106031_bib28","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.106031_bib29","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106031_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100273","article-title":"First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update","volume":"6","author":"Reck","year":"2021","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106031_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008189","article-title":"Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial","volume":"12","author":"Carbone","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmoop.2025.106031_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114296","article-title":"Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial","volume":"211","author":"Reck","year":"2024","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106031_bib33","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","article-title":"First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations","volume":"18","author":"Paz-Ares","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.106031_bib34","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.106031_bib35","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR","volume":"2020","author":"Ma","year":"2023","journal-title":"medRxiv"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106031_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37120","article-title":"Association of performance status with survival in patients with advanced non-small cell lung cancer treated with pembrolizumab monotherapy","volume":"4","author":"Sehgal","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmoop.2025.106031_bib37","author":"Rohatgi"},{"key":"10.1016\/j.esmoop.2025.106031_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"22","key":"10.1016\/j.esmoop.2025.106031_bib39","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1002\/cncr.32383","article-title":"Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer","volume":"125","author":"Khozin","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2025.106031_bib40","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1200\/CCI.20.00084","article-title":"Real-world outcomes for patients treated with immune checkpoint inhibitors in the Veterans Affairs System","volume":"4","author":"La","year":"2020","journal-title":"JCO Clin Cancer Inform"},{"issue":"18","key":"10.1016\/j.esmoop.2025.106031_bib41","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2217\/imt-2021-0145","article-title":"Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer","volume":"13","author":"Zhang","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.esmoop.2025.106031_bib42","article-title":"Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: real-world outcomes at US oncology practices","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.esmoop.2025.106031_bib43","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.2147\/CMAR.S376510","article-title":"Real-world outcomes and prognostic factors among patients with advanced non-small cell lung cancer and high PD-L1 expression treated with immune checkpoint inhibitors as first-line therapy","volume":"14","author":"Ge","year":"2022","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.esmoop.2025.106031_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.834761","article-title":"Long-term real-world outcomes of first-line pembrolizumab monotherapy for metastatic non-small cell lung cancer with \u226550% expression of programmed cell death-ligand 1","volume":"12","author":"Velcheti","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106031_bib45","article-title":"A real-world study on the effectiveness and safety of pembrolizumab plus chemotherapy for nonsquamous NSCLC","volume":"3","author":"Fujimoto","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"2","key":"10.1016\/j.esmoop.2025.106031_bib46","article-title":"First-line pembrolizumab plus chemotherapy for advanced squamous NSCLC: real-world outcomes at U.S. oncology practices","volume":"4","author":"Liu","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.esmoop.2025.106031_bib47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.lungcan.2019.12.011","article-title":"Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry","volume":"140","author":"Smit","year":"2020","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106031_bib48","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.3390\/curroncol28050357","article-title":"Effectiveness and safety of first-line pembrolizumab in older adults with PD-L1 positive non-small cell lung cancer: a retrospective cohort study of the Alberta Immunotherapy Database","volume":"28","author":"Grosjean","year":"2021","journal-title":"Curr Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.106031_bib49","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.1991.9.9.1618","article-title":"Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience","volume":"9","author":"Albain","year":"1991","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.106031_bib50","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.1995.13.5.1221","article-title":"Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party","volume":"13","author":"Paesmans","year":"1995","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2025.106031_bib51","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1001\/jamaoncol.2015.3151","article-title":"Risk adjusting survival outcomes in hospitals that treat patients with cancer without information on cancer stage","volume":"1","author":"Pfister","year":"2015","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.106031_bib52","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.jtho.2018.09.007","article-title":"Survival comparison in patients with stage IV lung cancer in academic versus community centers in the United States","volume":"13","author":"Ramalingam","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.106031_bib53","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/JOP.2016.020446","article-title":"Survival as a quality metric of cancer care: use of the National Cancer Data Base to assess hospital performance","volume":"14","author":"Shulman","year":"2018","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.esmoop.2025.106031_bib54","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/CCI.20.00125","article-title":"Comparisons of real-world time-to-event end points in oncology research","volume":"5","author":"Walker","year":"2021","journal-title":"JCO Clin Cancer Inform"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925019015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925019015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:54:25Z","timestamp":1773953665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925019015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2059702925019015"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106031","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.106031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106031"}}